AMERICAN HOSPITAL ASSOCIATION v. KENNEDY

What this may mean

The AbbVie rebate model plan for VRAYLAR directly implicates 340B-covered entities, including hospitals, that currently receive upfront discounts on the drug and would instead receive rebates under the proposed pilot. Hospitals and other 340B participants purchasing VRAYLAR for Medicare patients would face cash-flow and billing changes if the rebate model displaces the statutory discount at point of sale. The litigation posture suggests hospital plaintiffs are challenging CMS's authority to implement or permit this rebate model for IRA-negotiated drugs.

Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.